4,4'-(2'-aminospiro[chromeno[2,3-b]pyridine-5,4'-[1,3]oxazole]-3,7-diyl)bis(2-methyl-3-butyn-2-ol) | 1215865-59-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 4,4'-(2'-aminospiro[chromeno[2,3-b]pyridine-5,4'-[1,3]oxazole]-3,7-diyl)bis(2-methyl-3-butyn-2-ol)
• 英文别名: 4,4'-(-2'-Aminospiro[chromeno[2,3-b]pyridine-5,4'-[1,3]oxazole]-3,7-diyl)bis(2-methyl-3-butyn-2-ol)；4-[2-amino-3'-(3-hydroxy-3-methylbut-1-ynyl)spiro[5H-1,3-oxazole-4,5'-chromeno[2,3-b]pyridine]-7'-yl]-2-methylbut-3-yn-2-ol
• CAS: 1215865-59-0
• 化学式: C₂₄H₂₃N₃O₄
• 分子量: 417.464
• InChiKey: DWBFBHDYXHYUPZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  110
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-bromo-7-iodo-5'H-spiro[chromeno[2,3-b]pyridin-5,4′-oxazol]-2′-amine 、 2-甲基-3-丁炔-2-醇 在 四(三苯基膦)钯 copper(l) iodide 、 二异丙胺 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以13.17%的产率得到4,4'-(2'-aminospiro[chromeno[2,3-b]pyridine-5,4'-[1,3]oxazole]-3,7-diyl)bis(2-methyl-3-butyn-2-ol)
  参考文献：
  名称：

  [EN] SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE
  [FR] COMPOSÉS CYCLIQUES SPIRO-TÉTRACYCLIQUES UTILES EN TANT QUE MODULATEURS DE LA BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及一类新的化合物，用于调节β-分泌酶酶活性，并用于治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施例中，这些化合物具有一般的化学式（I）；其中化学式（I）中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z在此处定义。该发明还包括将这些化合物用于制备用于治疗与β-分泌酶蛋白活性相关的疾病和症状的药物组合物。这些疾病包括例如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症以及与大脑斑块的形成和/或沉积相关和/或由此引起的其他中枢神经系统疾病。该发明还涵盖了化学式I的进一步实施例、中间体和用于制备化合物的有用过程。

  公开号：

  WO2010030954A1

文献信息

• SPIRO-TRICYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE
  申请人：White Ryan

  公开号：US20100087429A1

  公开（公告）日：2010-04-08

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A 1 , A 2 , A 3 , A 4 , A 5 , A 6 , T 1 , T 2 , W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一类新化合物，可用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关病症。其中，一种实施方式是化合物具有通式I，其中通式I中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z的定义在此。本发明还包括这些化合物在制备用于治疗与beta-分泌酶蛋白活性相关的疾病和病症的药物组合物中的使用，包括阿尔茨海默病、认知障碍、认知损伤、精神分裂症和其他与大脑斑块的形成和/或沉积相关和/或由此引起的中枢神经系统病症。本发明还包括通式I的进一步实施方式、中间体和制备通式I化合物的有用过程。
• Spiro-tricyclic ring compounds as beta-secretase modulators and methods of use
  申请人：White Ryan

  公开号：US08426447B2

  公开（公告）日：2013-04-23

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula I are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula I.

  本发明涉及一种新的化合物类别，用于调节Beta-分泌酶酶活性和治疗Beta-分泌酶介导的疾病，包括阿尔茨海默病（AD）和相关疾病。在一种实施例中，该化合物具有一般的I式，其中I式中的A1，A2，A3，A4，A5，A6，T1，T2，W，X，Y和Z在此被定义。本发明还包括将这些化合物用于制备治疗性、预防性或治疗性的药物组合物，用于治疗与beta-分泌酶蛋白活性相关的疾病和病症。这些疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他与大脑斑块形成和/或沉积相关和/或由此引起的中枢神经系统疾病。本发明还包括I式的进一步实施例、中间体和有用于制备I式化合物的过程。
• SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE
  申请人：Amgen Inc.

  公开号：EP2328903B1

  公开（公告）日：2014-03-05
• US8426447B2
  申请人：——

  公开号：US8426447B2

  公开（公告）日：2013-04-23
• [EN] SPIRO-TETRACYCLIC RING COMPOUNDS AS BETASECRETASE MODULATORS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SPIRO-TÉTRACYCLIQUES UTILES EN TANT QUE MODULATEURS DE LA BÊTA-SÉCRÉTASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：AMGEN INC

  公开号：WO2010030954A1

  公开（公告）日：2010-03-18

  The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula (I); wherein A1, A2, A3, A4, A5, A6, T1, T2, W, X, Y and Z of Formula (I) are defined herein. The invention also includes use of these compounds in pharmaceutical compositions for treatment, prophylactic or therapeutic, of disorders and conditions related to the activity of beta-secretase protein. Such disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairment, schizophrenia and other central nervous system conditions related to and/or caused by the formation and/or deposition of plaque on the brain. The invention also comprises further embodiments of Formula I, intermediates and processes useful for the preparation of compounds of Formula (I).

  本发明涉及一类新的化合物，用于调节β-分泌酶酶活性，并用于治疗β-分泌酶介导的疾病，包括阿尔茨海默病（AD）及相关疾病。在一种实施例中，这些化合物具有一般的化学式（I）；其中化学式（I）中的A1、A2、A3、A4、A5、A6、T1、T2、W、X、Y和Z在此处定义。该发明还包括将这些化合物用于制备用于治疗与β-分泌酶蛋白活性相关的疾病和症状的药物组合物。这些疾病包括例如阿尔茨海默病、认知缺陷、认知障碍、精神分裂症以及与大脑斑块的形成和/或沉积相关和/或由此引起的其他中枢神经系统疾病。该发明还涵盖了化学式I的进一步实施例、中间体和用于制备化合物的有用过程。